Targeting Palbociclib-Resistant Estrogen Receptor-Positive Breast Cancer Cells via Oncolytic Virotherapy

Targeting Palbociclib-Resistant Estrogen Receptor-Positive Breast Cancer Cells via Oncolytic Virotherapy

While clinical responses to palbociclib have been promising, metastatic breast cancer remains incurable due to the development of resistance. We generated estrogen receptor-positive (ER+) and ER-negative (ER−) cell line models and determined their permissiveness and cellular responses to a...

Full description

Bibliographic Details
Main Authors: Nadiia Lypova, Lilibeth Lanceta, Alana Gibson, Stephanie Vega, Rodolfo Garza-Morales, Kelly M. McMasters, Jason Chesney, Jorge G. Gomez-Gutierrez, Yoannis Imbert-Fernandez
Format: Article
Language:English
Published: MDPI AG 2019-05-01
Series:Cancers
Subjects:
palbociclib
estrogen receptor
oncolytic adenovirus
breast cancer
virotherapy
CDK4/6
CDK4/6 inhibitors
therapy resistance
Online Access:https://www.mdpi.com/2072-6694/11/5/684

Similar Items

Similar Items